Inogen (INGN) Getting Somewhat Positive Press Coverage, Study Shows
News stories about Inogen (NASDAQ:INGN) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Inogen earned a news impact score of 0.17 on Accern’s scale. Accern also gave news articles about the medical technology company an impact score of 47.2592892477967 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
- See what the IHS Markit Score report has to say about Inogen Inc. (finance.yahoo.com)
- Inogen, Inc (INGN) EVP Alison Bauerlein Sells 6,667 Shares (americanbankingnews.com)
- $64.14 Million in Sales Expected for Inogen, Inc (NASDAQ:INGN) This Quarter (americanbankingnews.com)
- Zacks: Analysts Anticipate Inogen, Inc (NASDAQ:INGN) to Announce $0.28 Earnings Per Share (americanbankingnews.com)
- Inogen Inc Up 55.5% Since SmarTrend Uptrend Call (INGN) (mysmartrend.com)
INGN has been the subject of a number of recent research reports. Sidoti started coverage on Inogen in a research report on Tuesday, April 18th. They set a “neutral” rating and a $79.00 price objective for the company. Zacks Investment Research cut Inogen from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 2nd. Needham & Company LLC restated a “buy” rating and issued a $96.00 price target on shares of Inogen in a report on Wednesday, May 10th. Stifel Nicolaus lifted their price target on Inogen from $65.00 to $75.00 and gave the company a “hold” rating in a report on Wednesday, May 10th. Finally, J P Morgan Chase & Co lifted their price target on Inogen to $102.00 and gave the company an “overweight” rating in a report on Monday, June 26th. Three equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $91.60.
Inogen (NASDAQ INGN) traded up 0.10% during mid-day trading on Friday, reaching $91.52. The company’s stock had a trading volume of 154,951 shares. The firm has a market capitalization of $1.90 billion, a price-to-earnings ratio of 79.44 and a beta of 1.01. Inogen has a 1-year low of $50.24 and a 1-year high of $98.33. The firm has a 50-day moving average of $94.47 and a 200 day moving average of $82.23.
Inogen (NASDAQ:INGN) last issued its earnings results on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.10. Inogen had a return on equity of 12.45% and a net margin of 10.36%. The company had revenue of $64.10 million for the quarter, compared to analyst estimates of $59.99 million. During the same period in the prior year, the firm posted $0.25 EPS. The business’s revenue was up 17.4% compared to the same quarter last year. Equities analysts expect that Inogen will post $1.21 earnings per share for the current year.
In other Inogen news, Director Heath Lukatch sold 9,000 shares of the company’s stock in a transaction dated Tuesday, May 30th. The stock was sold at an average price of $88.52, for a total value of $796,680.00. Following the transaction, the director now directly owns 7,246 shares of the company’s stock, valued at approximately $641,415.92. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Ray Benjamin M. Anderson sold 4,445 shares of the company’s stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $81.05, for a total value of $360,267.25. Following the completion of the transaction, the director now directly owns 4,445 shares in the company, valued at $360,267.25. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 87,849 shares of company stock worth $7,894,719. Insiders own 5.31% of the company’s stock.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.